Exact Sciences Corp. announced today encouraging data from an ongoing colorectal cancer trial showing that its blood-based test can detect advanced precancerous lesions and growing tumors.
The findings showed that its blood-based colorectal cancer screening algorithm was able to correctly identify 88.3% of malignant colorectal cancer (CRC) cases and exhibited sensitivity of 31.2% for precancerous lesions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?